Could a vaccine help fight throat cancer? new trial tests promising combo
NCT ID NCT05232851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a vaccine (PDS0101) given alone or with an immunotherapy drug (pembrolizumab) can shrink HPV-related throat tumors before surgery. About 20 adults with advanced cancer that has spread to nearby lymph nodes will receive the treatment. The goal is to see if this approach can reduce tumor size and limit the amount of tissue that needs to be removed during surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A gentler path after surgery for HPV throat cancer?
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- At-Home cervical cancer screening could save lives in rural uganda
- Could a delayed booster still protect against HPV?
- New hope for head and neck cancer: which drug works best with radiation?